SpringWorks Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenue:
Product revenue, net
Other revenue
Total revenue
Operating expenses:
Cost of product revenue
Selling, general and administrative
Research and development
Total operating expenses
Loss from operations
Interest and other income:
Other income
Other (expense) income, net
Interest income, net
Interest and other income, net
Total interest and other income

Equity method investment loss
Net loss
Net gain attributable to extinguishment of Series A convertible preferred and Junior Series A convertible preferred units
Net loss per share, basic and diluted
Weighted average common shares outstanding, basic and diluted
Net loss per share, basic (in usd per share)
Net loss per share, diluted (in usd per share)
Weighted average common shares outstanding, basic (in shares)
Weighted average common shares outstanding, diluted (in shares)

Comments